News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

What if we would have watched it for six months? Like, I possibly couldn’t be here talking to you and have lived my life six ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG (NVS) reports a strong quarter with significant sales increases across key products and a record $6 billion in ...

Novartis reported a strong Q3 2024 with 9% YoY sales growth, largely driven by its top four drugs. Pluvicto and Leqvio saw significant growth, but investor disappointment stemmed from a revenue ...

And we also had important innovation highlights, which we'll talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP positive opinion in hormone receptor positive HER2 ...

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...